Medeva, the pharmaceuticals company, has signed an exclusive agreement to
market Wellcome's new hay fever treatment, Semprex-D, in the US.
Adams Laboratories, Medeva's US subsidiary which has a 220-strong sales
force specialising in respiratory products, will start marketing Semprex-D
this month on behalf of Wellcome's US arm, Burroughs Wellcome.
